Tech Company Financing Transactions

VaxInnate Funding Round

The Wellcome Trust, Canaan Partners and CHL Medical Partners joined a $30 million Series D capital raise for VaxInnate. The funding round was announced by the company on 5/6/2009.

Transaction Overview

Company Name
VaxInnate
Announced On
5/6/2009
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series D
Investors

The Wellcome Trust (Lead Investor) (Julie Eskay-Eagle)

Canaan Partners (Seth Rudnick)

CHL Medical Partners (Gregory Weinhoff)

HealthCare Ventures

MedImmune Ventures

New Leaf Venture Partners (Philippe Chambon)

Oxford Bioscience Partners (Ellen Baron)

Proceeds Purpose
The funds will be used for the development of the company's vaccines for infectious diseases that include influenza, human papillomavirus (HPV), respiratory syncytial virus (RSV) and dengue. Specifically, the Company plans to fund several clinical trials, including a Phase II clinical trial of its M2e universal flu vaccine and a Phase I clinical trial of its seasonal flu vaccine in an elderly population.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Cedar Brook Dr. 1
Cranbury, NJ 08512
USA
Phone
(609) 860-2260
Website
www.vaxinnate.com
Email Address
[email protected]
Overview
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy.
Profile
VaxInnate LinkedIn Company Profile
Social Media
VaxInnate Company Twitter Account
Company News
VaxInnate News
Facebook
VaxInnate on Facebook
YouTube
VaxInnate on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Wayne Pisano
  Wayne Pisano LinkedIn Profile  Wayne Pisano Twitter Account  Wayne Pisano News  Wayne Pisano on Facebook
Chief Financial Officer
Kathleen McGowan
  Kathleen McGowan LinkedIn Profile  Kathleen McGowan Twitter Account  Kathleen McGowan News  Kathleen McGowan on Facebook
Chief Scientific Officer
Lynda Tussey
  Lynda Tussey LinkedIn Profile  Lynda Tussey Twitter Account  Lynda Tussey News  Lynda Tussey on Facebook
VP - Manufacturing
Bruce Weaver
  Bruce Weaver LinkedIn Profile  Bruce Weaver Twitter Account  Bruce Weaver News  Bruce Weaver on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/6/2009: ExactTarget venture capital transaction
Next: 5/6/2009: WonderHill venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.